Could Artificial Intelligence Be About To Replace Your Doctor? November 02, 2021 - Global Investment Daily The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And in the bigger scenario of a massive $11-trillion-plus global healthcare industry, America is definitely not first. Americans are fed up, and a digital revolution that goes way beyond telemedicine is the only thing that will restore control. Fixing it is a highly disruptive, multi-trillion-dollar opportunity. Telemedicine, or ‘Telehealth’, will soar from $42 billion in 2018 to $400 billion in 2026. Healthcare IT alone will be worth $390 billion by 2024. But the biggest disruptor of them all may be medical apps. Source: Allied Market Research And the advantage just might go to a Canadian company with perhaps the most sophisticated AI the healthcare sector has ever seen … Because it was developed by, and trained by, a huge team of doctors and medical experts from all over the world. Now, it’s about to launch in North America. And plans to then go global. City by city. The company is Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) and the world has never seen anything like global library of medicine, nor CARA, the new doctor-developed AI that could be set to revolutionize the $11 trillion healthcare industry. CARA is personalized in every way. CARA, Treatment’s Digital Assistant assesses symptoms based on your actual information; CARA helps you to diagnose health problems, makes recommendations, tracks and monitors your symptoms and follows up with your healthcare every step of the way. From cradle to grave, CARA helps you and your entire family (including caregivers) manage healthcare. The technology is 100% proprietary and it’s ready to win over a massive consumer base that is begging for a healthcare revolution. THIS IS THE NEW STANDARD IN AI HEALTHCARE Medical apps are tapped to be the fastest-growing IT healthcare segment, with consumers starving for better services that they can actually control and understand. We’re just at the beginning of a complete revolution in the healthcare industry, and Treatment.com is the first to truly attempt to empower the consumer with AI that thinks like a doctor because it was trained by real doctors over the past six years. The team behind it has a near perfect track record in building and scaling IT infrastructure, particularly in the healthcare sector, with major rewards for investors. For the past 6 years, a team of over 40 global world-class medical experts have been working to build the AI infrastructure for CARA and Treatment.com International Inc. (CSE: TRUE; OTC: TREIF). The AI is already so sophisticated it’s been licensed by the University of Minnesota Medical School to teach and test medical students. SCALING A HEALTH TECH STARTUP TO A BILLION DOLLAR EXIT John Fraser, the co-founder and CEO of Treatment.com, is a 20-year software IT veteran, who has been laser focused on the healthcare industry, launching his career at the Minnesota Department of Health. He was the key architect of a statewide cancer surveillance system (at the time – the largest ever conducted in the world). He created an entire pathology-based library of everyone in Minnesota with cancer. It was the first time in IT history that anyone had attempted an endeavor of that magnitude. And it proved an invaluable resource that is still used today. Fraser took that success and ran with it, becoming a big name in the unicorn space, and an expert at scaling up tech products and building valuable intellectual property (IP). His first unicorn was Vision Share (now Abilities Network), an IT claims and eligibility service that upended insurance claim management and healthcare billing. Vision Share sold for over $1.2 billion in 2015. What he did with Vision Share was just the precursor to Treatment.com, and CARA. He built an IT claims and eligibility service that was adopted across the country and is now among the top providers to payers and insurance providers in the United States. And he’s not the only pioneer behind Treatment.com. This is an expert executive and management team that has formed the backbone of the ailing healthcare industry’s service revolution. Co-founder and chief medical officer Dr. Kevin Peterson is an IT healthcare superstar with 35 years experience at the University of Minnesota, where he built the ECRN system to fully automate clinical studies at scale. He is an expert in chronic disease management, health services, diabetes, bioinformatics and clinical trials in primary care. The company’s Chief Strategy Officer, Dr Paul Markham a veteran and influencer in the global healthcare tech space is driving the next phase of growth at Treatment.com. And AI pioneer David Poole, Treatment.com’s Director of AI Research, is a professor of Computer Science at the University of British Columbia and the chair of the Association for Uncertainty in Artificial Intelligence, as well as Fellow of the Association for the Advancement of Artificial Intelligence (AAAI). He was also bestowed the Canadian AI Association (CAIAC) Lifetime Achievement Award in 2013. THE RUSH FOR IT HEALTHCARE SOLUTIONS HAS ALREADY BEGUN This space is heating up—fast. UK-based Babylon Health, a telehealth startup, is set to go public in the U.S. via a $4.2-billion SPAC deal. Big money should be looking for better deals than this, though. Deals that prioritize and emphasize artificial intelligence. That’s what makes Babylon less attractive than it could be, says Treatment.com’s Dr. Keven Peterson. “Babylon has struggled to provide an effective [AI powered] clinical decision support product. Their revenues are based on their clinical telemedicine, which uses the weakness of their app to draw people into the telemedicine interaction,” Peterson said, commenting on the $4.2-billion SPAC deal. Treatment.com International (CSE: TRUE; OTC: TREIF) offers digital capabilities powered by AI that are stronger than anything thrown at the market to date. “Our stronger digital capabilities give us an edge on customer engagement. Furthermore, completion of our medical product will engage medical systems by providing powerful clinical decision support. Ultimately, our more powerful AI tool and greater provider engagement should give us a substantial competitive edge over this provider,” Peterson added. ADA Health is another new entrant in this exciting space, and it recently closed a $90-million funding round led by Bayer and Samsung, and it’s partnering with Novartis. In 8 months, it’s managed to sign on 10 new global partners, thanks in large part to the allure of its AI powered symptom assessment technology. Medical apps powered by AI are poised to explode precisely because the AI brings everything together, intelligently.This is where TRUE has the competitive edge. “This vast infrastructure works to simplify an incredibly complex picture that is given from the patients input and historical data,” says John Fraser, CEO of TRUE. “The AI absorbs all of the users inputs and background information and applies it to current symptomology – and then thinking like a doctor –provides a comprehensive and hyper-personalized diagnostic assessment with suggestions for immediate treatment and healing.” THIS TECH WON’T BE UNDER THE RADAR FOR LONG Americans are desperate for healthcare clarity; Treatment.com gives it to them. Googling symptoms does not. CARA isn’t a game of googling symptoms and coming up with the most-searched piece of potential, anxiety-causing misinformation. CARA uses your medical records and the power of sophisticated AI trained by doctors to assess your symptoms and get you the care that you need, seamlessly. But for investors, the opportunity may be far bigger. TRUE has both B2C and B2B capabilities. On the B2C side, Treatment.com is laser focused on leveraging AI powered CARA to empower individuals to gain control over their health and wellbeing. On the B2B side, the massive global health insurance market, surging toward $4 trillion, is likely to find CARA a goldmine of data, predictability and scalability. And remember, Fraser has experience with scaling businesses through these kinds of partnerships, having founded $1.2 billion healthcare SaaS unicorn Ability Networks – that scaled through insurance partnerships. All of this makes the underlying, 100% owned proprietary IP something that should have investor interest piqued. Keep this name on your radar as Treatment.com International (CSE: TRUE; OTC: TREIF) plans to launch it’s ground-breaking APP – ‘CARA’ – powered by the most comprehensive AI in the industry, before the end of this year. Other companies taking on the world’s health crises in their own way: The impact of psychedelics on mental health has been a subject of interest for decades. For some, the symptoms of anxiety and depression are alleviated by these substances' ability to alter perception and promote spiritual exploration, and Canada-based Field Trip Health (CSE:FTRP) is taking a lead in this emerging field. Field Trip taking a three-pronged approach in their work in the transformative psychedelic medicine sector. Not only are they involved in drug development, but they’re also involved in manufacturing and run a number of treatment clinics. Field Trip has hit the ground running. With clinics currently operating in Toronto, Los Angeles, and New York, they have plans to ramp up to 75 clinics – providing psychotherapy along with psychedelic treatments. In the past, pharmaceutical companies have been limited to marketing their drugs through prescription-only channels. This limits the marketing potential and the ability for a company to reach a large audience. Trillium Therapeutics Inc. (TSX:TRIL) has found a way to bypass this limitation by using biotechnology. They take live cells from animals and grow them in large amounts for use as medicine. The process is called "pharming" or "transgenic." It's an innovative approach that could change how we think about drug development and distribution of medicines worldwide. Trillum is a specialized biotechnology company that takes a unique approach on the industry, harnessing insights from nature to develop novel immunotherapies to treat cancer. Trillium’s products tackle such diseases as lymphoma and myeloma and other blood cancers. Oncolytics Biotech Inc. (TSX:ONC) is a biotechnology company specializing in the development of novel, smallpox-derived oncolytic viral therapies for cancer treatment. The company's lead product candidate, Toca 511 & Toca FC, has been granted Fast Track designation by the FDA for the treatment of patients with metastatic melanoma that cannot be removed by surgery or radiation therapy. Oncolytics Biotech Inc is committed to developing innovative therapies that address significant unmet medical needs and have the potential to significantly improve outcomes for patients with serious infections and cancer. Oncolytics Biotech got it start from a major series of discoveries based out of the University of Calgary and has grown significantly over the past two decades. Onoclytics’ primary product is REOLYSIN, a first-in-class, systemically administered, immuno-oncolytic virus created with the potential to act as a therapy for cancer patients. Namaste Technologies Inc (TSX.V:N) is a Canadian company that develops and sells innovative cannabis products, like the NamasteMD mobile app that connects Canadians to medical cannabis doctors and allows them to order securely online. They also provide "Namaste Vapes," which are vaporizers with no THC or CBD, but offer a variety of aromatherapy options. This company has been experiencing exponential growth in recent years thanks to their unique product offerings and dedication to improving access for patients seeking medical marijuana treatment through innovation. Through its subsidiaries, Namaste Technologies operates as a retailer of a variety of marijuana products, including vaporizers and other smoking accessories. The company sells its goods through e-commerce sites operating in 26 countries. In addition to its accessory business, Namaste also engages in product development and the distribution of medical cannabis products in Canada. The Hexo Corporation (TSX:HEXO), a Canadian company originally founded as Hydropothecary Corp., has been developing and distributing medical marijuana products since 2013. In 2017, it was the first cannabis producer approved to list its shares on a major North American stock exchange. The company is now gearing up for legalization of recreational use by adults in Canada next year with plans to offer a range of adult-use products. In Hexo’s fourth-quarter press release, the company shared some optimistic news regarding Truss’ progress, with Sebastien St-Louis, Hexo CEO and co-founder, explaining, “We are commanding significant market share in Quebec and this year we made major strides by launching Truss cannabis infused beverages in Canada in addition to our initial foray into the U.S. with Molson Coors, a world-class partner,” By. William Thomas ** IMPORTANT NOTICE AND DISCLAIMER -- PLEASE READ CAREFULLY! ** PAID ADVERTISEMENT. This article is a paid advertisement. GlobalInvestmentDaily.com and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher four hundred and fifty thousand US dollars to produce and disseminate four articles profiling the Company. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information. SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the companies’ products, the prospects for success of the Company’s to be launched health and wellness app – “CARA”, the reported scheduled release of CARA, the ability to acquire customers for CARA, and the projected growth and profit margins of the Company’s core product offerings. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the launch of CARA, competition, market saturation, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions. TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://GlobalInvestmentDaily.com/Terms-of-Use. If you do not agree to the Terms of Use http://GlobalInvestmentDaily.com/Terms-of-Use, please contact GlobalInvestmentDaily.com to discontinue receiving future communications. INTELLECTUAL PROPERTY. GlobalInvestmentDaily.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
Could Artificial Intelligence Be About To Replace Your Doctor? November 02, 2021 - Global Investment Daily The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And in the bigger scenario of a massive $11-trillion-plus global healthcare industry, America is definitely not first. Americans are fed up, and a digital revolution that goes way beyond telemedicine is the only thing that will restore control. Fixing it is a highly disruptive, multi-trillion-dollar opportunity. Telemedicine, or ‘Telehealth’, will soar from $42 billion in 2018 to $400 billion in 2026. Healthcare IT alone will be worth $390 billion by 2024. But the biggest disruptor of them all may be medical apps. Source: Allied Market Research And the advantage just might go to a Canadian company with perhaps the most sophisticated AI the healthcare sector has ever seen … Because it was developed by, and trained by, a huge team of doctors and medical experts from all over the world. Now, it’s about to launch in North America. And plans to then go global. City by city. The company is Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) and the world has never seen anything like global library of medicine, nor CARA, the new doctor-developed AI that could be set to revolutionize the $11 trillion healthcare industry. CARA is personalized in every way. CARA, Treatment’s Digital Assistant assesses symptoms based on your actual information; CARA helps you to diagnose health problems, makes recommendations, tracks and monitors your symptoms and follows up with your healthcare every step of the way. From cradle to grave, CARA helps you and your entire family (including caregivers) manage healthcare. The technology is 100% proprietary and it’s ready to win over a massive consumer base that is begging for a healthcare revolution. THIS IS THE NEW STANDARD IN AI HEALTHCARE Medical apps are tapped to be the fastest-growing IT healthcare segment, with consumers starving for better services that they can actually control and understand. We’re just at the beginning of a complete revolution in the healthcare industry, and Treatment.com is the first to truly attempt to empower the consumer with AI that thinks like a doctor because it was trained by real doctors over the past six years. The team behind it has a near perfect track record in building and scaling IT infrastructure, particularly in the healthcare sector, with major rewards for investors. For the past 6 years, a team of over 40 global world-class medical experts have been working to build the AI infrastructure for CARA and Treatment.com International Inc. (CSE: TRUE; OTC: TREIF). The AI is already so sophisticated it’s been licensed by the University of Minnesota Medical School to teach and test medical students. SCALING A HEALTH TECH STARTUP TO A BILLION DOLLAR EXIT John Fraser, the co-founder and CEO of Treatment.com, is a 20-year software IT veteran, who has been laser focused on the healthcare industry, launching his career at the Minnesota Department of Health. He was the key architect of a statewide cancer surveillance system (at the time – the largest ever conducted in the world). He created an entire pathology-based library of everyone in Minnesota with cancer. It was the first time in IT history that anyone had attempted an endeavor of that magnitude. And it proved an invaluable resource that is still used today. Fraser took that success and ran with it, becoming a big name in the unicorn space, and an expert at scaling up tech products and building valuable intellectual property (IP). His first unicorn was Vision Share (now Abilities Network), an IT claims and eligibility service that upended insurance claim management and healthcare billing. Vision Share sold for over $1.2 billion in 2015. What he did with Vision Share was just the precursor to Treatment.com, and CARA. He built an IT claims and eligibility service that was adopted across the country and is now among the top providers to payers and insurance providers in the United States. And he’s not the only pioneer behind Treatment.com. This is an expert executive and management team that has formed the backbone of the ailing healthcare industry’s service revolution. Co-founder and chief medical officer Dr. Kevin Peterson is an IT healthcare superstar with 35 years experience at the University of Minnesota, where he built the ECRN system to fully automate clinical studies at scale. He is an expert in chronic disease management, health services, diabetes, bioinformatics and clinical trials in primary care. The company’s Chief Strategy Officer, Dr Paul Markham a veteran and influencer in the global healthcare tech space is driving the next phase of growth at Treatment.com. And AI pioneer David Poole, Treatment.com’s Director of AI Research, is a professor of Computer Science at the University of British Columbia and the chair of the Association for Uncertainty in Artificial Intelligence, as well as Fellow of the Association for the Advancement of Artificial Intelligence (AAAI). He was also bestowed the Canadian AI Association (CAIAC) Lifetime Achievement Award in 2013. THE RUSH FOR IT HEALTHCARE SOLUTIONS HAS ALREADY BEGUN This space is heating up—fast. UK-based Babylon Health, a telehealth startup, is set to go public in the U.S. via a $4.2-billion SPAC deal. Big money should be looking for better deals than this, though. Deals that prioritize and emphasize artificial intelligence. That’s what makes Babylon less attractive than it could be, says Treatment.com’s Dr. Keven Peterson. “Babylon has struggled to provide an effective [AI powered] clinical decision support product. Their revenues are based on their clinical telemedicine, which uses the weakness of their app to draw people into the telemedicine interaction,” Peterson said, commenting on the $4.2-billion SPAC deal. Treatment.com International (CSE: TRUE; OTC: TREIF) offers digital capabilities powered by AI that are stronger than anything thrown at the market to date. “Our stronger digital capabilities give us an edge on customer engagement. Furthermore, completion of our medical product will engage medical systems by providing powerful clinical decision support. Ultimately, our more powerful AI tool and greater provider engagement should give us a substantial competitive edge over this provider,” Peterson added. ADA Health is another new entrant in this exciting space, and it recently closed a $90-million funding round led by Bayer and Samsung, and it’s partnering with Novartis. In 8 months, it’s managed to sign on 10 new global partners, thanks in large part to the allure of its AI powered symptom assessment technology. Medical apps powered by AI are poised to explode precisely because the AI brings everything together, intelligently.This is where TRUE has the competitive edge. “This vast infrastructure works to simplify an incredibly complex picture that is given from the patients input and historical data,” says John Fraser, CEO of TRUE. “The AI absorbs all of the users inputs and background information and applies it to current symptomology – and then thinking like a doctor –provides a comprehensive and hyper-personalized diagnostic assessment with suggestions for immediate treatment and healing.” THIS TECH WON’T BE UNDER THE RADAR FOR LONG Americans are desperate for healthcare clarity; Treatment.com gives it to them. Googling symptoms does not. CARA isn’t a game of googling symptoms and coming up with the most-searched piece of potential, anxiety-causing misinformation. CARA uses your medical records and the power of sophisticated AI trained by doctors to assess your symptoms and get you the care that you need, seamlessly. But for investors, the opportunity may be far bigger. TRUE has both B2C and B2B capabilities. On the B2C side, Treatment.com is laser focused on leveraging AI powered CARA to empower individuals to gain control over their health and wellbeing. On the B2B side, the massive global health insurance market, surging toward $4 trillion, is likely to find CARA a goldmine of data, predictability and scalability. And remember, Fraser has experience with scaling businesses through these kinds of partnerships, having founded $1.2 billion healthcare SaaS unicorn Ability Networks – that scaled through insurance partnerships. All of this makes the underlying, 100% owned proprietary IP something that should have investor interest piqued. Keep this name on your radar as Treatment.com International (CSE: TRUE; OTC: TREIF) plans to launch it’s ground-breaking APP – ‘CARA’ – powered by the most comprehensive AI in the industry, before the end of this year. Other companies taking on the world’s health crises in their own way: The impact of psychedelics on mental health has been a subject of interest for decades. For some, the symptoms of anxiety and depression are alleviated by these substances' ability to alter perception and promote spiritual exploration, and Canada-based Field Trip Health (CSE:FTRP) is taking a lead in this emerging field. Field Trip taking a three-pronged approach in their work in the transformative psychedelic medicine sector. Not only are they involved in drug development, but they’re also involved in manufacturing and run a number of treatment clinics. Field Trip has hit the ground running. With clinics currently operating in Toronto, Los Angeles, and New York, they have plans to ramp up to 75 clinics – providing psychotherapy along with psychedelic treatments. In the past, pharmaceutical companies have been limited to marketing their drugs through prescription-only channels. This limits the marketing potential and the ability for a company to reach a large audience. Trillium Therapeutics Inc. (TSX:TRIL) has found a way to bypass this limitation by using biotechnology. They take live cells from animals and grow them in large amounts for use as medicine. The process is called "pharming" or "transgenic." It's an innovative approach that could change how we think about drug development and distribution of medicines worldwide. Trillum is a specialized biotechnology company that takes a unique approach on the industry, harnessing insights from nature to develop novel immunotherapies to treat cancer. Trillium’s products tackle such diseases as lymphoma and myeloma and other blood cancers. Oncolytics Biotech Inc. (TSX:ONC) is a biotechnology company specializing in the development of novel, smallpox-derived oncolytic viral therapies for cancer treatment. The company's lead product candidate, Toca 511 & Toca FC, has been granted Fast Track designation by the FDA for the treatment of patients with metastatic melanoma that cannot be removed by surgery or radiation therapy. Oncolytics Biotech Inc is committed to developing innovative therapies that address significant unmet medical needs and have the potential to significantly improve outcomes for patients with serious infections and cancer. Oncolytics Biotech got it start from a major series of discoveries based out of the University of Calgary and has grown significantly over the past two decades. Onoclytics’ primary product is REOLYSIN, a first-in-class, systemically administered, immuno-oncolytic virus created with the potential to act as a therapy for cancer patients. Namaste Technologies Inc (TSX.V:N) is a Canadian company that develops and sells innovative cannabis products, like the NamasteMD mobile app that connects Canadians to medical cannabis doctors and allows them to order securely online. They also provide "Namaste Vapes," which are vaporizers with no THC or CBD, but offer a variety of aromatherapy options. This company has been experiencing exponential growth in recent years thanks to their unique product offerings and dedication to improving access for patients seeking medical marijuana treatment through innovation. Through its subsidiaries, Namaste Technologies operates as a retailer of a variety of marijuana products, including vaporizers and other smoking accessories. The company sells its goods through e-commerce sites operating in 26 countries. In addition to its accessory business, Namaste also engages in product development and the distribution of medical cannabis products in Canada. The Hexo Corporation (TSX:HEXO), a Canadian company originally founded as Hydropothecary Corp., has been developing and distributing medical marijuana products since 2013. In 2017, it was the first cannabis producer approved to list its shares on a major North American stock exchange. The company is now gearing up for legalization of recreational use by adults in Canada next year with plans to offer a range of adult-use products. In Hexo’s fourth-quarter press release, the company shared some optimistic news regarding Truss’ progress, with Sebastien St-Louis, Hexo CEO and co-founder, explaining, “We are commanding significant market share in Quebec and this year we made major strides by launching Truss cannabis infused beverages in Canada in addition to our initial foray into the U.S. with Molson Coors, a world-class partner,” By. William Thomas ** IMPORTANT NOTICE AND DISCLAIMER -- PLEASE READ CAREFULLY! ** PAID ADVERTISEMENT. This article is a paid advertisement. GlobalInvestmentDaily.com and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher four hundred and fifty thousand US dollars to produce and disseminate four articles profiling the Company. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information. SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the companies’ products, the prospects for success of the Company’s to be launched health and wellness app – “CARA”, the reported scheduled release of CARA, the ability to acquire customers for CARA, and the projected growth and profit margins of the Company’s core product offerings. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the launch of CARA, competition, market saturation, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions. TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://GlobalInvestmentDaily.com/Terms-of-Use. If you do not agree to the Terms of Use http://GlobalInvestmentDaily.com/Terms-of-Use, please contact GlobalInvestmentDaily.com to discontinue receiving future communications. INTELLECTUAL PROPERTY. GlobalInvestmentDaily.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.